Prognostic significance of POLE proofreading mutations in endometrial cancer

Journal of the National Cancer Institute

Volumn 107, Issue 1, 2015, Pages

  Church, David N ^a,b   Stelloo, Ellen ^c   Nout, Remi A ^c   Valtcheva, Nadejda ^d   Depreeuw, Jeroen ^e   Haar, Natalja Ter ^c   Noske, Aurelia ^d   Amant, Frederic ^f,g   Tomlinson, Ian P M ^a   Wild, Peter J ^d   Lambrechts, Diether ^e,f   Jürgenliemk Schulz, Ina M ^h   Jobsen, Jan J ⁱ   Smit, Vincent T H B M ^c   Creutzberg, Carien L ^c   Bosse, Tjalling ^c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^f University of Leuven   (Belgium)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁱ MEDISCH SPECTRUM TWENTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DNA POLYMERASE; DNA POLYMERASE POLE; UNCLASSIFIED DRUG; DNA DIRECTED DNA POLYMERASE ALPHA; POLE PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; GENE MUTATION; GENE SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; CANCER GRADING; DISEASE FREE SURVIVAL; ENDOMETRIUM TUMOR; GENETICS; KAPLAN MEIER METHOD; META ANALYSIS; MORTALITY; MUTATION; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RISK;

ADULT; DISEASE-FREE SURVIVAL; DNA POLYMERASE II; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MUTATION; NEOPLASM GRADING; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84925545509     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/dju402     Document Type: Article

References (31)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374-1403.
2. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol. 1989;96(8):889-892.
3. Creutzberg CL, van Putten WL, Koper PC, et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomized trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet. 2000;355(9213):1404-1411.
4. Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomized trial. Lancet. 2010;375(9717):816-823.
5. Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomized studies. Eur J Cancer. 2010;46(13):2422-2431.
6. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol. 2006;24(1):36-44.
7. Murali R, Soslow RA, Weigelt B. Classification of endometrial carcinoma: more than two types. Lancet Oncol. 2014;15(7):e268-e278.
8. Nout RA, Bosse T, Creutzberg CL, et al. Improved risk assessment of endometrial cancer by combined analysis of MSI, PI3K-AKT, Wnt/beta-catenin and P53 pathway activation. Gynecol Oncol. 2012;126(3):466-473.
9. Garcia-Dios DA, Lambrechts D, Coenegrachts L, et al. Highthroughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma. Gynecol Oncol. 2012;10:1-8.
10. Palles C, Cazier J-B, Howarth KM, et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas. Nat Genet. 2013;45(2):136-144.
11. Church DN, Briggs SE, Palles C, et al. DNA polymerase epsilon and delta exonuclease domain mutations in endometrial cancer. Hum Mol Genet. 2013;22(14):2820-2828.
12. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497(7447):67-73.
13. Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013;500(7463):415-421.
14. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut. 2008;57(7):941-950.
15. Hutchins G, Southward K, Handley K, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261-1270.
16. Bertagnolli MM, Redston M, Compton CC, et al. Microsatellite instability and loss of heterozygosity at chromosomal location 18q: prospective evaluation of biomarkers for stages II and III colon cancer - a study of CALGB 9581 and 89803. J Clin Oncol. 2011;29(23):3153-3162.
17. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium. Gynecol Oncol. 2014;134(1):15-19.
18. Simon RM, Paik S, Hayes DF. Use of Archived Specimens in Evaluation of Prognostic and Predictive Biomarkers. J Natl Cancer Inst. 2009;101(21):1446-1452.
19. Wild PJ, Ikenberg K, Fuchs TJ, et al. p53 suppresses type II endometrial carcinomas in mice and governs endometrial tumor aggressiveness in humans. EMBO Mol Med. 2012;4(8):808-824.
20. Seshagiri S, Stawiski EW, Durinck S, et al. Recurrent R-spondin fusions in colon cancer. Nature. 2012;488(7413):660-664.
21. Heitzer E, Tomlinson I. Replicative DNA polymerase mutations in cancer. Curr Opin Genet Dev. 2014;24:107-113.
22. McShane LM, Altman DG, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180-1184.
23. Altman DG, McShane LM, Sauerbrei W, et al. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med. 2012;9(5):e1001216.
24. Heinze G, Schemper M. A solution to the problem of monotone likelihood in Cox regression. Biometrics. 2001;57(1):114-119.
25. Gallo ML, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44(12):1310-1315.
26. Zhao S, Choi M, Overton JD, et al. Landscape of somatic singlenucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci U S A. 2013;110(8):2916-2921.
27. Creutzberg CL, van Putten WL, Warlam-Rodenhuis CC, et al. Outcome of high-risk stage IC, grade 3, compared with stage I endometrial carcinoma patients: the Postoperative Radiation Therapy in Endometrial Carcinoma Trial. J Clin Oncol. 2004;22(7):1234-1241.
28. Herr AJ, Kennedy SR, Knowels GM, et al. DNA replication errorinduced extinction of diploid yeast. Genetics. 2014;196(3):677-691.
29. Kane DP, Shcherbakova PV. A common cancer-associated DNA polymerase å mutation causes an exceptionally strong mutator phenotype, indicating fidelity defects distinct from loss of proofreading. Cancer Res. 2014;74(7):1895-1901.
30. McFarland CD, Korolev KS, Kryukov GV, et al. Impact of deleterious passenger mutations on cancer progression. Proc Natl Acad Sci U S A. 2013;110(8):2910-2915.
31. Zou Y, Liu FY, Liu H, et al. Frequent POLE1 p. S297F mutation in Chinese patients with ovarian endometrioid carcinoma. Mutat Res. 2014;761:49-52.